Announcements | Pfizer Medical Information

Announcement	Date
Pfizer and Biontech Conclude Phase 3 Study of Vaccine Candidate, Meeting All Primary Efficacy Endpoints	November 18, 2020
Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study	November 9, 2020
Norpace CR Drug Shortage Communication – Supply Status	October 19, 2020
U.S. FDA Approves Xeljanz (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA)	September 30, 2020
Approval from German authority to start clinical trial of COVID-19 vaccine	April 23, 2020
COVID-19 Information Update for U.S. Health Care Professionals	April 15, 2020
U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy. On April 8th, 2020, Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAFV600E mutation, as detected by an FDA-approved test, after prior therapy. The approval is based on results from the BEACON CRC trial, the only Phase 3 trial to specifically study patients with previously treated metastatic CRC with a BRAFV600E mutation.	April 8, 2020
Pfizer Advances Battle Against COVID-19 on Multiple Fronts	April 1, 2020
COVID-19 MRNA VACCINE DEVELOPMENT PROGRAM: FIRST PARTICIPANTS IN THE U.S. First participants dosed at NYU Grossman School of Medicine and University of Maryland School of Medicine. Pfizer and BioNTech ramping up manufacturing capabilities to further increase production capacity in 2020/2021	April 1, 2020
Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development	April 1, 2020
Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine	April 1, 2020

All announcements